Insulet Corporation (PODD)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Insulet Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 165.40 $ — 12% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
9 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 27.5% passed
- More than 10% revenue growth is expected for the coming year 18.5% passed
- Share count grows by less than 3% a year 0.9% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 44.7% passed
- Gross margin at 40% or higher and without meaningful erosion 71.6% passed
- Goodwill from acquisitions does not grow faster than revenue 1.6% passed
- Net debt below twice EBITDA 0.6 x EBITDA passed
- Operating cash flow covers the profits of the last three years 274 m passed
- Return on capital at 15% or higher, or up versus two years ago 18.9% passed
- Insiders hold at least 10% or are net buyers 0.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 42.4% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 24
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6.48 | 6.37 – 6.59 | 3,320 | 30.4% | 23 |
| 12/31/2027 | 8.05 | 7.38 – 8.36 | 3,927 | 24.3% | 23 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.44 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.36 | -8.10 | 598 | 17.20 | 16.90 | 148 | 92 |
| 2025: Q1 | 0.48 | -31.60 | 569 | 28.80 | 6.20 | 64 | 52 |
| 2025: Q2 | 0.32 | -87.50 | 649 | 32.90 | 3.50 | 197 | 173 |
| 2025: Q3 | 1.24 | 18.30 | 706 | 29.90 | 12.40 | 126 | 105 |
| 2025: Q4 | 1.44 | 5.80 | 784 | 31.20 | 13.00 | 183 | 48 |
| 2026: Q1 | 1.30 | 171.70 | 762 | 33.90 | 12.00 | 114 | 86 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 367 | -11 | -29 | -0.50 | 16 | 63 | 457 |
| 2017 | 464 | -7 | -27 | -0.46 | 41 | 159 | 817 |
| 2018 | 564 | 27 | 3 | 0.05 | 36 | 212 | 929 |
| 2019 | 738 | 50 | 12 | 0.19 | 98 | 76 | 1,143 |
| 2020 | 904 | 52 | 7 | 0.10 | 84 | 604 | 1,873 |
| 2021 | 1,099 | 126 | 17 | 0.25 | -68 | 556 | 2,049 |
| 2022 | 1,305 | 38 | 5 | 0.07 | 119 | 476 | 2,251 |
| 2023 | 1,697 | 220 | 206 | 2.80 | 146 | 733 | 2,588 |
| 2024 | 2,072 | 309 | 418 | 5.66 | 430 | 1,212 | 3,088 |
| 2025 | 2,708 | 474 | 247 | 3.44 | 569 | 1,515 | 3,190 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Insulet Corporation entwickelt, fertigt und verkauft Insulinverabreichungssysteme für insulinabhängige Diabetiker in den USA und international. Das Unternehmen bietet Omnipod-Plattformprodukte an, darunter das automatisierte Insulinverabreichungssystem Omnipod 5 mit proprietärem Algorithmus.
| Employees | 5,400 |
|---|---|
| Headquarters | Acton, MA |
| Address | 100 Nagog Park, 01720 Acton, United States |
| Phone | 978 600 7000 |
| Website | insulet.com |
| IPO Date | 15. May 2007 |
| ISIN | US45784P1012 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Ashley A. McEvoy | CEO, President & Director | 1971 |
| Flavia H. Pease | Executive VP & CFO | 1973 |
| Eric Benjamin | Executive VP & COO | 1983 |
| John Wodick Kapples J.D. | Senior VP & General Counsel | 1960 |
| Prem Singh | Senior Vice President of Global Operations | 1977 |
| Amit Guliani | Senior VP & CTO | – |
| Clare Trachtman | Vice President of Investor Relations | – |
| Chuck Medovich | Senior VP and Chief Quality, Regulatory & Compliance Officer | – |
| Angela Geryak Wiczek | Senior Director of Corporate Communications | – |
| Philip Hildale | Senior Vice President of Sales & Customer Care | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.